Shift

Cerevance Announces Presentation at AD/PD™ 2024 International Conference

Retrieved on: 
Tuesday, February 27, 2024
Shift, Therapy, Epigenomics, Central nervous system, Alzheimer's disease, KCNK10, Astrocyte, Date, Conference, Mechanism, CNS, Gene, DSM-IV codes

BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a virtual and onsite poster at the upcoming AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Lisbon, Portugal from March 5-9, 2024.

Key Points: 
  • BOSTON, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, today announced plans to present a virtual and onsite poster at the upcoming AD/PD™ 2024 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders, taking place in Lisbon, Portugal from March 5-9, 2024.
  • Overview: The NETSseq platform produces deep transcriptomic and epigenomic profiles from post-mortem human brain tissue.
  • One of these genes, KCNK10, is specifically expressed in astrocytes and oligodendrocytes, and its role in regulating glutamate uptake has been validated.
  • Therapeutic Targets, Mechanisms for Treatment: Astroglia; Poster Shift 2: Friday, March 8 - Saturday, March 9, 2024

Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, February 20, 2024
Shift, Acquisition, DSM-IV codes, Fibromyalgia, Central nervous system, Total, New Drug Application, MD, Narcolepsy, FDA, Marketing, Smoking, Food, Somnolence, Growth, SYMPHONY, Reboxetine, Psychiatry, Dextromethorphan/bupropion, Migraine, FOCUS, Safety, Therapy, Medicare, NMDA, CNS, Food and Drug Administration, BED, Webcast, Depression, Binge eating disorder, Patient, Agitation, Shirin David, Medicaid, SWD, Breakthrough therapy, MDD, NDA, Prescription, Pharmaceutical industry

Auvelity® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch.

Key Points: 
  • Auvelity® net product sales were $49.0 million and $130.1 million for the fourth quarter and full year of 2023, the first full year of launch.
  • Total costs of revenue were $7.4 million and $26.1 million for the fourth quarter and full year of 2023, respectively.
  • Approximately 84,000 prescriptions were written for Auvelity in the fourth quarter of 2023, representing a 23% sequential increase versus the third quarter of 2023.
  • Axsome will host a conference call and webcast today at 8:00 AM Eastern to discuss fourth quarter and full year 2023 financial results as well as to provide a corporate update.

SolarWinds Sponsors SQLBits 2024, Europe’s Largest Data Platform Conference

Retrieved on: 
Tuesday, March 5, 2024
Software, Technology, Internet, Data Management, Shift, SolarWinds, Artificial intelligence, SQL, SWI, Fire, Root cause analysis, Software as a service, DevOps, Gold, Communication, Big data, Machine learning

SQLBits is Europe’s largest data platform conference, featuring 200 world-class speakers, more than 300 hours of content, and engaging networking opportunities.

Key Points: 
  • SQLBits is Europe’s largest data platform conference, featuring 200 world-class speakers, more than 300 hours of content, and engaging networking opportunities.
  • Attendees can deepen their knowledge of everything from the SQL Server® product suite and transactional data systems to the latest trends in big data, analytics, artificial intelligence (AI), and machine learning.
  • “SolarWinds database performance monitoring and observability solutions provide deep visibility and performance insight by simplifying the management of your most complex databases.
  • The SolarWinds database portfolio includes SolarWinds® Database Performance Analyzer for performance monitoring and analysis, SolarWinds SQL Sentry® for root cause analysis, and SolarWinds Database Observability , a SaaS solution built for DevOps and designed to help ensure optimal performance by monitoring open-source, cloud-enabled, and NoSQL databases.

Global Cold Chain Market for Pharmaceuticals Research Report 2024: Market Trends (2019-2022) and Forecasted Estimates (2023-2035) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 28, 2024
Manufacturing, Health, Pharmaceutical, Packaging, Chemicals, Plastics, Shift, Acquisition, Carbon footprint, Temperature, Import and export, Growth, Usability, Cold, Risk, Safety, Insulation, Type, Fine chemical

This market report features an extensive study of the current market landscape, market size and future opportunities associated with the temperature controlled packaging in pharma cold chain market, during the forecast period.

Key Points: 
  • This market report features an extensive study of the current market landscape, market size and future opportunities associated with the temperature controlled packaging in pharma cold chain market, during the forecast period.
  • One of the primary objectives addressed in this market report was the estimation of the current market size and the future growth potential within the cold chain market for pharmaceuticals in the upcoming years.
  • Through a thorough consideration of various parameters, anticipated adoption trends, and validated by primary research, the report provides informed estimates on the expected evolution of the cold chain market for pharmaceuticals during the forecast period from 2023 to 2035.
  • Recent advancements in the cold chain monitoring market have revolutionized the cold chain industry.

Global Respiratory Infection Diagnostic Market Research Report 2024-2028 with Executive and Consultant Guides - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 28, 2024
Infectious Diseases, Health, Medical Supplies, Medical Devices, Shift, COVID-19, SARS-CoV-2, Tempus

5.26 QuantuMDx Developing Multiplex System, Syndromic Panels

Key Points: 

5.26 QuantuMDx Developing Multiplex System, Syndromic Panels
5.39 Tempus Announces COVID-19 Testing, Data Initiative
5.42 Companies Shift to Multiplex Tests for SARS-CoV-2, Influenza
5.43 Novacyt Gets CE Mark for Coronavirus, Flu, RSV Combo Panel

Alzheon to Present Biomarker, Brain Preservation, and Clinical Results from Pivotal Program of Oral ALZ-801/Valiltramiprosate at International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

Retrieved on: 
Tuesday, February 27, 2024
Research, Neurology, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Shift, Wuxi, Doctor of Philosophy, WuXi AppTec, MD, Risk, Conference, Unit, Cerebral edema, Biomarker, Patient, Drug, NDA, DSM-IV codes

“The new treatment landscape for Alzheimer’s disease is beginning to take shape, and Alzheon’s simplified approach has an opportunity to transform the standard of care and improve access to treatment for Alzheimer’s patients.

Key Points: 
  • “The new treatment landscape for Alzheimer’s disease is beginning to take shape, and Alzheon’s simplified approach has an opportunity to transform the standard of care and improve access to treatment for Alzheimer’s patients.
  • ALZ-801’s efficacy data and favorable safety profile, showing no increased risk of vasogenic edema, underscore the differentiated clinical profile of our treatment,” said Martin Tolar, MD, PhD, Founder, President, and CEO of Alzheon.
  • Results from our pivotal APOLLOE4 Phase 3 trial will set the stage for the potential NDA filing this year and commercial launch in 2025.”
    Alzheon presentations include two posters and two symposium presentations.
  • If the results of our study are positive, we will be moving quickly to bring an oral option to Alzheimer’s patients and their families,” said John Hey, PhD, Chief Scientific Officer.

Walker Sands’ Research Reveals Emphasis on Outcomes in Evaluating Marketing Impact

Retrieved on: 
Wednesday, February 21, 2024
Marketing, Digital Marketing, Communications, Search Engine Marketing, Content Marketing, Other Communications, Public Relations, Investor Relations, Shift, Great Resignation, OBM, Integration, Walker, CMOS, Learning, Pressure, SVP

This disconnect is at the core of the findings in a new report from Walker Sands , a full-service B2B marketing agency.

Key Points: 
  • This disconnect is at the core of the findings in a new report from Walker Sands , a full-service B2B marketing agency.
  • Surveying more than 150 marketing leaders and 50 non-marketing C-suite executives, the Outcome-based Marketing: The Case for a Perspective-Shift in B2B Marketing report unveiled the top challenges B2B marketers are facing to achieve results that contribute to business outcomes, especially as the B2B marketing landscape continues to evolve.
  • 86% of C-suite executives feel their marketing teams struggle to demonstrate the impact marketing activities have on business success.
  • The majority (73%) first focus on activating specific marketing channels and achieving KPIs, and then connect metrics back to the outcomes.

Growth Opportunity in the Global Passenger Vehicle Shift-by-Wire Market - Forecasts to 2030: SBW Industry Faces Transformation and Decline Amid EV Proliferation and Evolving E/E Architecture - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 21, 2024
Other Automotive, Automotive Manufacturing, Manufacturing, Automotive, Shift, SBW, Tier 2, Electronics, Original equipment manufacturer, Renewable energy

The "Growth Opportunity in the Global Passenger Vehicle Shift-by-Wire Market" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Growth Opportunity in the Global Passenger Vehicle Shift-by-Wire Market" report has been added to ResearchAndMarkets.com's offering.
  • This comprehensive study examines the global shift-by-wire (SBW) market from 2022 to 2030, providing insights into growth prospects and their associated implications.
  • This study outlines growth drivers and restraints set to impact regional and global market dynamics.
  • The report explores the SBW technology penetration across different global regions, examining a wide array of factors and emerging market trends.

Infinix Tops Charts with Largest Year-on-Year Shipments Increase Among Global Smartphone Brands in 2023

Retrieved on: 
Friday, March 8, 2024
Shift, MWC, Worldwide, Business, Overseas, CES, IDC, Environment

SHANGHAI, March 8, 2024 /PRNewswire/ -- Infinix, a trendy tech brand crafted for young consumers, is thrilled to announce its exceptional performance in 2023. According to IDC's Worldwide Quarterly Mobile Phone Tracker, Infinix has achieved a remarkable milestone in year-on-year increase in units in smartphone shipments, surpassing all other global smartphone brands with an astounding accomplishment of over 13 million units increase. This translates to an impressive growth rate of 64.1% compared to 2022.

Key Points: 
  • According to IDC's Worldwide Quarterly Mobile Phone Tracker, Infinix has achieved a remarkable milestone in year-on-year increase in units in smartphone shipments, surpassing all other global smartphone brands with an astounding accomplishment of over 13 million units increase.
  • By utilizing the platform, Infinix successfully connects with its target users, empowering them to exceed their limitations and unlock their full potential.
  • Infinix also introduced Infinix E-Color Shift, the industry's first customizable display panel for smartphone appearances.
  • As 2024 unfolds, Infinix is poised to lead the way with more groundbreaking innovations, setting the stage for an exciting future.

Infinix Tops Charts with Largest Year-on-Year Shipments Increase Among Global Smartphone Brands in 2023

Retrieved on: 
Friday, March 8, 2024
Shift, MWC, Worldwide, Business, Overseas, CES, IDC, Environment

SHANGHAI, March 8, 2024 /PRNewswire/ -- Infinix, a trendy tech brand crafted for young consumers, is thrilled to announce its exceptional performance in 2023. According to IDC's Worldwide Quarterly Mobile Phone Tracker, Infinix has achieved a remarkable milestone in year-on-year increase in units in smartphone shipments, surpassing all other global smartphone brands with an astounding accomplishment of over 13 million units increase. This translates to an impressive growth rate of 64.1% compared to 2022.

Key Points: 
  • According to IDC's Worldwide Quarterly Mobile Phone Tracker, Infinix has achieved a remarkable milestone in year-on-year increase in units in smartphone shipments, surpassing all other global smartphone brands with an astounding accomplishment of over 13 million units increase.
  • By utilizing the platform, Infinix successfully connects with its target users, empowering them to exceed their limitations and unlock their full potential.
  • Infinix also introduced Infinix E-Color Shift, the industry's first customizable display panel for smartphone appearances.
  • As 2024 unfolds, Infinix is poised to lead the way with more groundbreaking innovations, setting the stage for an exciting future.